Cargando…

Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1

Purpose: This study aims to determine whether semiquantitative parameters obtained from both the primary tumor and metastatic pelvic lymph nodes (PLN) diagnosed in fluoro-18-deoxy-glucose positron emission tomography (FDG-PET-CT) are associated with disease-free survival (DFS), local control (LC), d...

Descripción completa

Detalles Bibliográficos
Autores principales: Burchardt, Ewa, Burchardt, Wojciech, Cegła, Paulina, Kubiak, Anna, Roszak, Andrzej, Cholewiński, Witold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073234/
https://www.ncbi.nlm.nih.gov/pubmed/33923621
http://dx.doi.org/10.3390/diagnostics11040714
_version_ 1783684083338969088
author Burchardt, Ewa
Burchardt, Wojciech
Cegła, Paulina
Kubiak, Anna
Roszak, Andrzej
Cholewiński, Witold
author_facet Burchardt, Ewa
Burchardt, Wojciech
Cegła, Paulina
Kubiak, Anna
Roszak, Andrzej
Cholewiński, Witold
author_sort Burchardt, Ewa
collection PubMed
description Purpose: This study aims to determine whether semiquantitative parameters obtained from both the primary tumor and metastatic pelvic lymph nodes (PLN) diagnosed in fluoro-18-deoxy-glucose positron emission tomography (FDG-PET-CT) are associated with disease-free survival (DFS), local control (LC), distant metastasis-free survival (DMFS) and overall survival (OS) in patients with locally advanced squamous cervical cancer (LACC) and metastatic pelvic lymph nodes. Materials: Retrospective analysis was performed on 93 female patients with FIGO IIIC1. The median age was 53 years (27–75). The PET parameters both in the primary tumor and metastatic pelvic lymph nodes, including SUVmax, SUVmean, TLG, MTV, heterogeneity, along with clinical variables, before radical cisplatin-based radiochemotherapy (RCT) were analyzed. The p-values < 0.05 were considered statistically significant. Results: Median follow-up was 38 months (4.5–92.6). Three years and five years OS were 75% and 70% respectively. Patients with SUVmax above 12.6, SUVmean above 7.6 and with TLG in tumors >245.7 lived longer (p < 0.05). The higher SUVmax or SUVmean reduced increased DMFS (HR 0.3 95%CI 0.56–0.96 and 0.59 95%CI 0.37–0.93). The clinical factors and other FDG PET CT parameters were not found to be statistically relevant in terms of OS, DFS, DM and LC. Conclusions: This study is the first report showing that in LACC patient population with PLN involvement treated with definitive RCT, high SUVmean, SUVmax and TLG of the primary tumor in FDG-PET-CT were linked with longer OS. Lower SUVmean and SUVmax were linked with shorter DMFS. None of the clinical factors and the nodal FDG-PET-CT parameters influenced the outcome.
format Online
Article
Text
id pubmed-8073234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80732342021-04-27 Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1 Burchardt, Ewa Burchardt, Wojciech Cegła, Paulina Kubiak, Anna Roszak, Andrzej Cholewiński, Witold Diagnostics (Basel) Article Purpose: This study aims to determine whether semiquantitative parameters obtained from both the primary tumor and metastatic pelvic lymph nodes (PLN) diagnosed in fluoro-18-deoxy-glucose positron emission tomography (FDG-PET-CT) are associated with disease-free survival (DFS), local control (LC), distant metastasis-free survival (DMFS) and overall survival (OS) in patients with locally advanced squamous cervical cancer (LACC) and metastatic pelvic lymph nodes. Materials: Retrospective analysis was performed on 93 female patients with FIGO IIIC1. The median age was 53 years (27–75). The PET parameters both in the primary tumor and metastatic pelvic lymph nodes, including SUVmax, SUVmean, TLG, MTV, heterogeneity, along with clinical variables, before radical cisplatin-based radiochemotherapy (RCT) were analyzed. The p-values < 0.05 were considered statistically significant. Results: Median follow-up was 38 months (4.5–92.6). Three years and five years OS were 75% and 70% respectively. Patients with SUVmax above 12.6, SUVmean above 7.6 and with TLG in tumors >245.7 lived longer (p < 0.05). The higher SUVmax or SUVmean reduced increased DMFS (HR 0.3 95%CI 0.56–0.96 and 0.59 95%CI 0.37–0.93). The clinical factors and other FDG PET CT parameters were not found to be statistically relevant in terms of OS, DFS, DM and LC. Conclusions: This study is the first report showing that in LACC patient population with PLN involvement treated with definitive RCT, high SUVmean, SUVmax and TLG of the primary tumor in FDG-PET-CT were linked with longer OS. Lower SUVmean and SUVmax were linked with shorter DMFS. None of the clinical factors and the nodal FDG-PET-CT parameters influenced the outcome. MDPI 2021-04-16 /pmc/articles/PMC8073234/ /pubmed/33923621 http://dx.doi.org/10.3390/diagnostics11040714 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Burchardt, Ewa
Burchardt, Wojciech
Cegła, Paulina
Kubiak, Anna
Roszak, Andrzej
Cholewiński, Witold
Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title_full Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title_fullStr Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title_full_unstemmed Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title_short Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
title_sort pretreatment [(18)f]fdg pet/ct prognostic factors in patients with squamous cell cervical carcinoma figo iiic1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073234/
https://www.ncbi.nlm.nih.gov/pubmed/33923621
http://dx.doi.org/10.3390/diagnostics11040714
work_keys_str_mv AT burchardtewa pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1
AT burchardtwojciech pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1
AT cegłapaulina pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1
AT kubiakanna pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1
AT roszakandrzej pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1
AT cholewinskiwitold pretreatment18ffdgpetctprognosticfactorsinpatientswithsquamouscellcervicalcarcinomafigoiiic1